ALK+ Metastatic Non-Small Cell Lung Cancer: The Importance of Biomarker Testing

The FDA approved the Ventana MET RxDx assay, making it the first companion diagnostic to aid in determining MET protein expression in non-squamous NSCLC.

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met protein overexpression.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

Lung cancer remains the leading cause of cancer-related deaths in the U.S.

LCI has appointed Neal Ready, MD, PhD, as its first Chief Scientific Officer.